DUPIXENT® mechanism of action1*

DUPIXENT® is a human monoclonal antibody that specifically binds to the IL-4Rα subunit shared by receptor complexes for IL-4 and IL-131*

Showing the mechanism of action of DUPIXENT. The image shows a type 2 receptor with IL-4Ra and IL-13Ra subunits. Above the receptor is the DUPIXENT monoclonal antibody, IL-4 and IL-13. DUPIXENT inhibits IL-4 and IL-13 signalling by binding to the IL-4Ra subunit shared by the IL-4 and IL-13 receptor complexes.
Adapted from the Product Monograph.
 

IL-4 and IL-13 are key type 2 (including Th2) cytokines involved in atopic disease.

The mechanism of action for dupilumab in asthma has not been definitively established.

DUPIXENT® pharmacodynamics in asthma

DUPIXENT® was associated with decreases in the following biomarkers of inflammation consistent with inhibition of IL-4 and IL-13 signalling:1*

  • These reductions were consistent between the 200 mg Q2W and 300 mg Q2W regimens, and were sustained throughout treatment
  • Near maximal reductions were observed after 2 weeks of exposure (except IgE, which declined more slowly)


FeNO=fractional exhaled nitric oxide; IgE=immunoglobulin E; IL=interleukin; IL-4R=interleukin-4 receptor; TARC=thymus and activation-regulated chemokine.
* Clinical significance is unknown.

Connect With a Rep

Have questions about DUPIXENT®? Get answers from a representative.

Freedom support program logo.

Freedom Support Program

Find out what the Freedom Support Program can bring to your patients.


Sanofi Regeneron Logo

DUPIXENT® (dupilumab injection) logo


DUPIXENT®, Sanofi and Freedom logos are trademarks of Sanofi, used under license by sanofi-aventis Canada Inc.
REGENERON® is a trademark of Regeneron Pharmaceuticals, Inc. All rights reserved.
© 2023 sanofi-aventis Canada Inc. All rights reserved.

MAT-CA-2300228
Last updated: 06/2023


Innovative Medicines Canada logo PAAB logo